E. Herrmann

P. Saftig, H. Pavenstädt, Gilles A. Spoden, 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients

M. Relling, C. Pui, Wenjian Yang, 2012, Clinical Cancer Research.

The calcium-activated chloride channel Anoctamin 1 contributes to the regulation of renal function.

R. Witzgall, H. Pavenstädt, R. Schreiber, 2014, Kidney international.

Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder

C. Stief, M. Hohenfellner, J. Ellinger, 2011, BJU international.

Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib

L. Hertle, E. Herrmann, S. Bierer, 2011, World Journal of Urology.

The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma

C. Stief, M. Stöckle, B. Wullich, 2022, Urologia Internationalis.

Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study

L. Bergmann, P. Goebell, T. Steiner, 2013, Oncology Research and Treatment.

Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.

L. Hertle, E. Eltze, C. Wülfing, 2008, Oncology reports.

Artificial Urinary Sphincter Cuff Size Predicts Outcome in Male Patients Treated for Stress Incontinence: Results of a Large Central European Multicenter Cohort Study

A. Schrader, R. Kirschner-Hermanns, R. Bauer, 2019, International neurourology journal.

The role of the endothelin axis and microvessel density in bladder cancer - correlation with tumor angiogenesis and clinical prognosis.

L. Hertle, M. Bögemann, E. Eltze, 2007, Oncology reports.

New tools for assessing the individual risk of metastasis in renal cell carcinoma

M. Steinhoff, L. Krabbe, C. Weishaupt, 2012, Clinical & Experimental Metastasis.

Preoperative anemia and extensive transfusion during stay-in-hospital are critical for patient`s mortality: A retrospective multicenter cohort study of oncological patients undergoing radical cystectomy.

M. Eveslage, H. Van Aken, A. Haferkamp, 2018, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Combined Immunochemotherapy in Selected Patients With Metastatic Renal Cell Carcinoma: HLA Class II Genotype Can Help to Predict Response to Therapy

J. Gerss, L. Hertle, R. Kelsch, 2011, Journal of immunotherapy.

Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model

C. Bremer, L. Hertle, C. Bolenz, 2009, Journal of Cancer Research and Clinical Oncology.

Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks.

C. Stief, M. Hohenfellner, J. Ellinger, 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Association Between the Number of Dissected Lymph Nodes During Pelvic Lymphadenectomy and Cancer-Specific Survival in Patients with Lymph Node–Negative Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy

C. Stief, M. Hohenfellner, J. Ellinger, 2011, Annals of Surgical Oncology.

Lymphangiogenesis occurs in upper tract urothelial carcinoma and correlates with lymphatic tumour dissemination and poor prognosis

P. Alken, C. Bolenz, L. Trojan, 2009, BJU international.

Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres

A. Ganser, V. Grünwald, A. Merseburger, 2014, Medical Oncology.

Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta

S. Shariat, B. Wullich, R. Palisaar, 2015, World Journal of Urology.

External validation of a risk model to predict recurrence-free survival after radical cystectomy in patients with pathological tumor stage T3N0 urothelial carcinoma of the bladder.

C. Stief, M. Hohenfellner, J. Ellinger, 2012, The Journal of urology.

The role of lymphangiogenesis in lymphatic tumour spread of urological cancers

S. Ergün, C. Bolenz, L. Trojan, 2009, BJU international.

Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder.

C. Stief, M. Hohenfellner, D. Dragun, 2012, Gender medicine.

Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a.

C. Stief, M. Hohenfellner, J. Ellinger, 2013, Urologic oncology.

Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma

M. Grimm, T. Steiner, E. Herrmann, 2011, World Journal of Urology.

New tools for assessing the individual risk of metastasis in renal cell carcinoma

M. Steinhoff, L. Krabbe, C. Weishaupt, 2013, Clinical & Experimental Metastasis.

The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians

B. Hadaschik, C. Stief, M. Wirth, 2017, Clinical genitourinary cancer.

Clearance of refractory bile duct stones with Extracorporeal Shockwave Lithotripsy: higher failure rate in obese patients

D. Domagk, W. Domschke, E. Herrmann, 2014, Scandinavian journal of gastroenterology.

EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer

R. Knuechel, T. Ecke, N. Gaisa, 2020, Oncogene.

Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC).

L. Krabbe, A. Schrader, E. Herrmann, 2014, Current cancer drug targets.

Systemic therapy in metastatic renal cell carcinoma

H. Tesch, T. Gauler, K. Miller, 2016, World Journal of Urology.

Serum Hepcidin and GDF-15 levels as prognostic markers in urothelial carcinoma of the upper urinary tract and renal cell carcinoma

A. Schrader, M. Eveslage, L. Traeger, 2019, BMC Cancer.

MicroRNAs in Renal Cell Carcinoma: Diagnostic Implications of Serum miR-1233 Levels

Stefan Holdenrieder, Volker Jung, Frank Becker, 2011, PloS one.

Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients

U. Capitanio, C. Stief, T. Klatte, 2017, World Journal of Urology.

Promoter methylation inhibits expression of tumor suppressor KIBRA in human clear cell renal cell carcinoma

H. Pavenstädt, S. Brand, E. Brand, 2017, Clinical Epigenetics.

Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA subtype project)

U. Capitanio, C. Stief, T. Klatte, 2017, Scandinavian journal of urology.

Update on systemic therapies of metastatic renal cell carcinoma

C. Wülfing, E. Herrmann, S. Bierer, 2010, World Journal of Urology.

Serum Hepcidin and GDF-15 levels as prognostic markers in urothelial carcinoma of the upper urinary tract and renal cell carcinoma

A. Schrader, M. Eveslage, L. Traeger, 2019, BMC Cancer.

[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].

P. Alken, C. Bolenz, L. Trojan, 2009, Aktuelle Urologie.

External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder.

P. Karakiewicz, M. Hohenfellner, Maxine Sun, 2012, European urology.

Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study

G. Bartsch, M. Grimm, J. Ellinger, 2018, Urologia Internationalis.

First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

M. Staehler, V. Grünwald, P. Goebell, 2020, International journal of cancer.

Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents

L. Hertle, C. Wülfing, E. Herrmann, 2009, Expert review of anticancer therapy.

Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer

A. Semjonow, L. Krabbe, A. Schrader, 2016, BMC Cancer.

VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival.

L. Hertle, E. Eltze, C. Wülfing, 2007, Anticancer research.

Protein Abundance of Clinically Relevant Drug Transporters in The Human Kidneys

H. Pavenstädt, U. Neugebauer, S. Oswald, 2019, International journal of molecular sciences.

Prognostic factors of papillary renal cell carcinoma: results from a multi-institutional series after pathological review.

J. Gerss, M. Staehler, C. Stief, 2010, The Journal of urology.

High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma.

H. Höfler, M. Staehler, C. Stief, 2019, Human pathology.

Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node‐negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial

C. Stief, M. Hohenfellner, C. Bolenz, 2010, BJU international.

The prognostic impact of pelvic lymph node metastasis and lymphovascular invasion on bladder cancer

L. Hertle, C. Bolenz, C. Wülfing, 2008, International journal of urology : official journal of the Japanese Urological Association.

GDF15 and Hepcidin as Prognostic Factors in Patients with Prostate Cancer

A. Semjonow, L. Hertle, M. Eveslage, 2014 .

Lymphovascular invasion and pathologic tumor stage are significant outcome predictors for patients with upper tract urothelial carcinoma.

P. Alken, C. Bolenz, L. Trojan, 2008, Urology.

Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil.

L. Hertle, M. Bögemann, C. Wülfing, 2007, European Urology.

Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma

A. Hartmann, H. Taubert, S. Wach, 2017, Scientific Reports.

Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder

C. Stief, M. Hohenfellner, J. Ellinger, 2011, Scandinavian journal of urology and nephrology.

Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy.

C. Stief, M. Hohenfellner, J. Ellinger, 2011, European urology.

Expression of nectin-4 in papillary renal cell carcinoma

M. Stöckle, A. Hartmann, B. Wullich, 2022, Discover Oncology.

New clues for nephrotoxicity induced by ifosfamide: preferential renal uptake via the human organic cation transporter 2.

G. Burckhardt, H. Pavenstädt, R. Kleta, 2011, Molecular pharmaceutics.

The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications

L. Hertle, M. Bögemann, E. Eltze, 2006, Expert review of anticancer therapy.

Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy - A Prospective Multicenter Study

C. Stief, M. Wirth, M. Grimm, 2015, Urologia Internationalis.

Expression of the Endothelin-axis in the different histologic subtypes of renal cell carcinoma: a tissue microarray analysis.

L. Hertle, E. Eltze, C. Wulfing, 2007, Oncology reports.

[New markers for pharmacological targeting in bladder cancer with lymph node metastasis].

L. Hertle, C. Bolenz, E. Eltze, 2007, Aktuelle Urologie.

External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder.

C. Stief, M. Hohenfellner, J. Ellinger, 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study

L. Bergmann, P. Goebell, T. Steiner, 2015, BMC Cancer.

Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer.

L. Bergmann, P. Goebell, A. Schrader, 2014, European urology.

Expression and predictive value of lymph-specific markers in urothelial carcinoma of the bladder.

J. von Hardenberg, C. Schubert, C. Bolenz, 2014, Urologic oncology.

[Influence of older age on survival after radical cystectomy due to urothelial carcinoma of the bladder: survival analysis of a German multi-centre study after curative treatment of urothelial carcinoma of the bladder].

C. Stief, M. Hohenfellner, J. Ellinger, 2011, Der Urologe (Ausg. A).

845OPhase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II)

Uwe Zimmermann, J. Gschwend, M. Wirth, 2017 .

A. Semjonow, L. Krabbe, A. Schrader, 2016, BMC Cancer.

Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma